E. TAROLLA, A. D’ANDREA, T. CANTELMI - Vol. 9, June 2003, Issue 2
Testo Immagini Bibliografia Summary Indice
Paroxetina: tossicità, tollerabilità
e usi atipici nella pratica clinica
Paroxetine: toxicity, tolerability and atypical use in clinical practice
1 Perugi G, Frare F, Toni C, Ruffolo G, Moretti L, Torti C. Up to date su paroxetina. Indicazioni terapeutiche, effetti collaterali, interazioni e modalità d’uso. Studi di psichiatria 2002;4(Suppl 1):S1-S24.
2 Wagstaff AJ, Cheer SM, Matheson AJ, Omrod D, Goa KL. Paroxetine. An update of its use in psychiatric disorders in adults. Drugs 2002;62:655-703.
3 Mori S, Perez J, Tardito D. I citocromi p450. Dalla biologia alla terapia antidepressiva. Milano: Masson 1999.
4 Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37.
5 Pasquini M, Speca A. Effetti tossici degli SSRI. In: Loriedo C, Di Fabio F, Vella G, eds. Gli SSRI nella pratica clinica. Milano: Masson 2001:177-99.
6 Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59(Suppl 15):45-8.
7 Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000;151:951-7.
8 Geretsegger C, Stuppaeck CH, Mair M, Platz T, Fartacek R, Heim M. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl) 1995;119:277-81.
9 Mulsant BH, Pollock BG, Nebes RD, Miller MD, Little JT, Stack J, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999;60(Suppl 20):16-20.
10 Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl 1989;350:132-4.
11 Dunner DL, Cohn JB, Walshe T 3rd, Cohn CK, Feighner JP, Fieve RR, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53(Suppl 2):57-60.
12 Schöne W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine and in geriatric patients with major depression. J Clin Psychopharmacol 1993;13(Suppl 2):34S-39S.
13 Trappler B, Cohen CI. Use of SSRIs in ‘very old’ depressed nursing home residents. Am J Geriatric Psychiatry 1998;6:83-9.
14 Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors : a prospective controlled multicenter study. JAMA 1998:279:609-10.
15 Ericson A, Kallen B, Wilholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clinical Pharmacol 1999;55:503-8.
16 Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatry 2001;90:288-91.
17 Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163-6.
18 Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000;157:185-9.
19 Begg EJ, Duffull SB, Saunders DA, Buttimore RC, Ilett KF, Hackett LP, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999;48:142-7.
20 Mantua V, Di Fabio F. Effetti collaterali degli SSRI. In: Loriedo C, Di Fabio F, Vella G, eds. Gli SSRI nella pratica clinica. Milano: Masson 2001:121-41.
21 Leo RJ. Movement disorders associated with the selective serotonin reuptake inhibitors. J Clin Psychiatry 1996;57:449-54.
22 Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacocynetics properties, and therapeutic potential in depressive illness. Drugs 1991;41:225-53.
23 Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998;56:85-120.
24 Robbe HW, O’Hanlon JF. Acute and subchronic effects of paroxetina 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995;5:5-42.
25 Frey R, Schreinzer D, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S. Suicide by antidepressant intoxication identified by autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 2000;10:133-42.
26 Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000;68:435-42.
27 De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population case-control study. BMJ 1999;319:1106-9.
28 Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996;155:519-27.
29 Strachan J, Sheperd J. Hyponatremia associated with the use of selective serotonin re-uptake inhibitors. Aust N Z J Psychiatry 1998;32:295-8.
30 Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord 1984;7:133-8.
31 Ackerman S, Nolan LJ. Body weight gain induced by psychotropic drugs: incidence, mechanisms and management. CNS Drugs 1998;9:135-51.
32 Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(Suppl 11):37-41.
33 Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunctions among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
34 Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;152:1514-6.
35 Bauer M, Zaninelli R, Muller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol 1999;19:164-71.
36 Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12.
37 Ravindran AV, Lapierre YD, Anisman H. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine. Can J Psychiatry 1999;44:805-7.
38 Lepkifker E, Dannon PN, Ziv R, Iancu I, Horesch N, Kotler M. The treatment of kleptomania with serotonin reuptake inhibitors. Clin Neuropharmacol 1999;22:40-3.
39 Block C, West SA, Baharoglu B. Paroxetine treatment of trichotillomania in an adolescent. J Child Adolesc Psychopharmacol 1998;8:69-71.
40 Reid TL. Treatment of resistant trichotillomania with paroxetine. Am J Psychiatry 1994;151:290.
41 Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002;63:501-7.
42 Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but no major depression. Am J Psychiatry 1998;155:543-7.
43 Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P. Double-blind placebo-controlled study of paroxetine for specific phobia. Psychopharmacology 2000;149:194-6.
44 Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13:100-8.
45 Muller U, Murai T, Bauer-Wittmund T, von Cramon DY. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999;13:805-11.
46 Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-6.
47 Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-52.
48 Ansari T. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harvard Rev Psychiatry 2000;5:257-77.
49 Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002;63:38-43.
50 Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractary vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999;5:1227-30.
51 Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.
52 Weitzner MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002;23:337-45.
53 McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hypocloride. Int J Impot Res 1999;11:241-5.
54 Salonia A, Maga T, Colombo R. Scattoni V, Briganti A, Cestari A, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002;168:2486-9.